Anti-Factor H is a highly specific enzyme immunoassay for the quantitative determination of IgG autoantibodies against factor H, in human serum or plasma.
Hemolytic uremic syndrome (HUS) is a disease of the small blood vessels, characterized by hemolytic anemia, thromocytopenia and acute renal failure (incidence in children in Central Europe is 7 in 1 million). The most common cause is infection with toxin producing Escherichia coli strains (shiga toxin, vero toxin). Up to 10 % of severe manifestations are fatal. Approximately 5 % of HUS patients show no signs of E. Coli infection, and also do not present diarrheal diseas. This so-called atypical HUS is caused by a disturbance in the regulation of the alternative complement system. In addition to mutation of the genes of the complement system, an acquired dysfunction of the complement regulator factor H through targeted antibodies can be a cause. According to an international consensus agreement (Loirat et al. 2015), all patients with suspected atypical HUS are to be tested for these antibodies before treatment, such as plasmapheresis, is initiated.